EU/3/06/409

Table of contents

About

On 27 October 2006, orphan designation (EU/3/06/409) was granted by the European Commission to Erytech Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes for the treatment of acute lymphoblastic leukaemia.

Key facts

Active substance
L-asparaginase encapsulated in erythrocytes
Disease / condition
Treatment of acute lymphoblastic leukaemia
Date of decision
27/10/2006
Outcome
Positive
Orphan decision number
EU/3/06/409

Sponsor's contact details

Erytech Pharma S.A.
60, avenue Rockefeller
69008 Lyon
France
Telephone: +33 4 78 74 44 38
Telefax: +33 4 78 75 56 29
E-mail: science@erytech.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating